KaMhlushwa DJ optimistic about being a famous radio presenter
DJ Makhekhe, real name Bongani Mashele (24), is forging a path in the broadcasting industry, showcasing his passion and dedication for connecting with listeners and encouraging people to dance.
Mashele said his career began in 2017 at an online radio platform, Pocket Stereo FM, where he spent two years honing his craft.
'I did not know anything about radio, so I gained experience at that station. This also opened a lot of opportunities to work at KaMhlushwa Online Radio for more than two years doing the weekend breakfast show,' Mashele said.
ALSO READ: Young Ehlanzeni athletes win medals at national champs
In 2021, he joined KRadio to refine his on-air presence and then moved on to Voice of Hope FM. With a wealth of experience under his belt, Mashele said he is looking forward to the next chapters in his career.
He is hoping to work in mainstream radio for Ligwalagwala FM, which would align with his professional growth aspirations, allowing him to further develop his skills and continue serving his loyal followers and listeners.
ALSO READ: Music, food and fun at Mbombela Farmers Market
As a side hustle, Mashele is a DJ and he plays at clubs and events. He is also a versatile music connoisseur, playing a variety of music such as amapiano, old school house, Afropop, soul and R&B.
At Caxton, we employ humans to generate daily fresh news, not AI intervention. Happy reading!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fwww.gannett-cdn.com%2Fauthoring%2Fimages%2FDataSkriveSportsbookWire%2F2025%2F04%2F16%2FSSBK%2F83116869007-14991234.jpeg%3Fauto%3Dwebp%26crop%3D1199%2C676%2Cx0%2Cy73%26format%3Dpjpg%26width%3D1200&w=3840&q=100)
![2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fusatoday.com.png&w=48&q=75){kind=small}
USA Today
27 minutes ago
- USA Today
2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview
2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview Carson Branstine (No. 231 ranking) will take on Elena-Gabriela Ruse (No. 80) in the Round of 16 of the Libema Open on Thursday, June 12. Ruse is the favorite against Branstine for this match, with -275 odds against the the underdog's +270. Tennis odds courtesy of BetMGM Sportsbook. Odds updated Wednesday at 6:35 PM ET. For a full list of sports betting odds, access USA TODAY Sports Betting Scores Odds Hub. Carson Branstine vs. Elena-Gabriela Ruse matchup info Tournament: Libema Open Libema Open Round: Round of 16 Round of 16 Date: Thursday, June 12 Thursday, June 12 Court Surface: Grass Watch the Tennis Channel and more sports on Fubo! Branstine vs. Ruse Prediction Based on the implied probility from the moneyline, Branstine has a 73.3% to win. Branstine vs. Ruse Betting Odds Branstine vs. Ruse matchup performance & stats
CNBC
27 minutes ago
- CNBC
Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says
Elon Musk's official role in the Trump administration recently came to an end. Many Republicans won't be sad to see less of him, according to the results of Quinnipiac University's latest public opinion survey. While a majority of Republicans still hold a favorable view of Musk, the number fell to 62% in the poll out Wednesday, down from 78% in March, Quinnipiac said. Overall, the Quinnipiac poll found that 30% of self-identified voters surveyed in the U.S. hold a favorable opinion of Musk, according to polling from June 5 to June 9. Republican and Democratic voters remain deeply divided in their views of the world's richest man, who contributed nearly $300 million to propel President Donald Trump back to the White House. Only 3% of Democrats surveyed said they held a favorable of view of the Tesla CEO, who was once seen as an environmental leader appealing to liberal values. Musk didn't respond to a request for comment. Musk and Trump had a very public falling out last week that started with Musk's disapproval of the president's spending bill and escalated into an all-out war of words that played out on social media. Musk said on Wednesday that he regretted some of the posts he made about Trump last week, adding that "they went too far." Even with a slide in his favorability, Musk is still popular among Republicans after his time running the Department of Government Efficiency (DOGE), an effort to dramatically slash the size of the federal government. Among the Republican respondents to the early June poll, 80% rated Musk and DOGE's work as either excellent or good, while 13% said it was either not so good or poor. In the March poll, 82% of Republicans surveyed said they thought Musk and DOGE were helping the country. Read the full survey results here.
Yahoo
27 minutes ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
